Use of an integrated pan-cancer oncology enrichment NGS assay to measure tumour mutational burden and detect clinically actionable variants
Valerie Pestinger, Matthew Ryan Smith, Toju Sillo, John M. Findlay, Jean‐François Laes, Gerald Martin, Gary Middleton, Phillipe Taniere, Andrew David Beggs
The paper evaluates the TruSight Oncology 500 assay for measuring tumour mutational burden and detecting clinically actionable variants, showing strong correlation with whole genome sequencing and orthogonal methods.
Molecular Diagnosis & Therapy · Apr 18, 2020Peer-reviewedGenetic & Genomic Medicine